-
Cipla vs Lupin 2027: Same Rs 29,000 Cr Revenue
- November 17, 2026
- Posted by: Ankit Jaiswal
- Category: Market
No Comments
Cipla vs Lupin 2027: both reported about Rs 29,040 crore of FY26 revenue, yet Lupin earned Rs 5,356 crore of profit against Rs 3,870 crore for Cipla and trades at less than half its P/E. Here is the full comparison.
-
Aarti Pharmalabs Analyst Review 2027
- November 17, 2026
- Posted by: Kunal Singla
- Category: Market
Aarti Pharmalabs posted record Q2 FY27 revenue of ₹610 crore with EBITDA up 80% and profit more than doubling. With no current dated brokerage target, we review the recovery, CDMO and xanthine plans, valuation and risks for 2027.
-
Aarey Drugs Analyst Review 2027
- November 17, 2026
- Posted by: Kunal Singla
- Category: Market
Aarey Drugs & Pharmaceuticals has more than doubled from its 52-week low, yet it earned just ₹1.37 crore in Q2 FY27 and has no brokerage coverage. We look at the numbers behind the rally, margins, valuation and risks for 2027.
-
Alkem Laboratories Analyst Review 2027: Sales Up 14%, Profit Down 12%, and a Tax Rate That Tripled
- November 17, 2026
- Posted by: Kunal Singla
- Category: Market
Alkem grew Q2 FY27 revenue 13.8% and EBITDA 11.3%, yet profit fell 11.7% as its tax rate jumped to 33%. We review five brokerage targets from ₹4,638 to ₹6,890, the India and export businesses, and the risks for 2027.
-
Abbott India Analyst Review 2027: A 38.7% ROE, a 2.5% Dividend Yield and Targets Up to ₹36,457. Why Is the Stock Flat?
- November 17, 2026
- Posted by: Chaitanya Auti
- Category: Market
Abbott India pairs a 38.7% ROE and near-zero debt with a 2.5% dividend yield, yet the stock sits near its 52-week low. We cover targets from ICICI Securities and BOB Capital, Q2 FY27 numbers, the brand model and 2027 triggers.
-
Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Which Stock Should You Track
- September 23, 2026
- Posted by: Harsh Piplani
- Category: Market
Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of September 2026.
- 1
- 2